The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Accelerating Biological Understanding and Therapeutic Translation for PD-Biology, 2025Validating Hallmarks of Inflammation in a Preclinical Alpha-synuclein Model of Parkinson’s Disease
Study Rationale: Inflammation and abnormal protein clumps in the brain are strongly associated with Parkinson's disease (PD). To study the mechanism of inflammation and disease progression related to...
-
Parkinson’s Disease Therapeutics Pipeline Program, 2025(SUPPLEMENT) Discovery of Translational Biomarkers for Endolysosomal Pathway Pathology Using Lipidomics and Metabolomics
Study Rationale: The endolysosomal system in living cells is comprised of small, specialized structures that contain enzymes that degrade proteins and remove molecular waste. Impaired function of this...
-
Accelerating Biological Understanding and Therapeutic Translation for PD-Biology, 2025GBA1 Consortium: Joint Analysis to Inform Clinical Trials
Study Rationale: Variants in the GB1A gene represent the most important genetic risk factor for Parkinson’s disease (PD) across the globe. However, different GBA1 variants are associated with varied...
-
Neuronal Synuclein Disease Endotypes 2024, 2025Development of Alpha-synuclein Seed Amplification Assay in Cerebrospinal Fluid as a Robust Biomarker of Synucleinopathies
Study Rationale: Progressive aggregation of alpha-synuclein and the subsequent loss of affected brain cells starts 10 to 20 years before the onset of Parkinson’s disease (PD) symptoms. Early diagnosis...
-
Accelerating Biological Understanding and Therapeutic Translation for PD-Biomarkers, 2024Investigating the Early Events in Parkinson’s Disease Pathobiology through Longitudinal Evaluation of Asymptomatic Carriers of Alpha-synuclein Mutations
Study Rationale: Essentially nothing is known about the sequence of biological and physiological events that ultimately lead to the clinical manifestations of Parkinson’s disease (PD). The existence...
-
Accelerating Biological Understanding and Therapeutic Translation for PD-Biology, 2024Characterization of a Preclinical Model Bearing a Parkinson’s Disease–linked Mutation in PLA2G6
Study Rationale: Mutations in the PLA2G6 gene lead to neurodegeneration linked to Parkinson’s disease (PD), but the mechanism is unknown. The gene encodes an enzyme that breaks down the lipid...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.